Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insider Analysis From Asia Pacific Bio Intelligence LLC On China State FDA’s Medical Device Regulations

This article was originally published in PharmAsia News

Executive Summary

For China’s State FDA, 2011 was a banner year, with regulations released on good manufacturing practices for both drugs and devices. Multinational companies should take notice and be sure their operations are in compliance.

You may also be interested in...



New Guidelines Shed Light On Private Investment In China Hospitals

SHANGHAI - China's capital Beijing and Zhejiang Province recently issued long-awaited guidelines to encourage private investment in medical institutions, which is viewed by analysts as a signal that China will implement the policy nationwide and open the gates for private hospitals

What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)

SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus

China Beefs Up Quality Control System With New GMP Regulations: Shanghai FDA Leaders At PharmAsia Summit

SAN FRANCISCO - China is releasing a new edition of its good manufacturing practice regulations and introducing other measures to strength its pharmaceutical quality control system. China's State FDA is placing more focus on reviewing drugs for approval while provincial-level regulators have stepped-up responsibility for inspecting drug makers and monitoring drugs on the market, said Shanghai FDA officers who spoke at the PharmAsia Summit this week in San Francisco

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC079316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel